Introduction
Previous studies have employed many strategies to mediate gene transfer into hematopoietic cells. Of particular interest, due to their central role in hematopoietic development, has been the transduction of primitive hematopoietic stem and progenitor cells. [1] [2] [3] [4] To date, the vast majority of studies have utilized retroviral vectors; however, more recently alternatives such as adeno-associated virus (AAV) vectors and lentivirus vectors have been reported. [5] [6] [7] [8] All of these vectors can mediate stable insertion into the host cell genome and are therefore appropriate for applications where permanent genetic alternations are desired. However, use of retroviral and AAV systems for primitive hematopoietic cells has been problematic. For example, conventional Moloney leukemia virus (MLV)-based vectors require cellular replication to achieve Correspondence: CT Jordan, Markey Cancer Center, 800 Rose St, Room CC407, Lexington, KY, 40536-0093, USA; Fax: 606 257 7715 Received 11 May 1999; accepted 22 June 1999 stable integration. This is of course a significant problem for transduction of primitive hematopoietic cells which are largely quiescent. Lentiviral vectors can integrate into some types of non-dividing cells, but have not yet been clearly shown to transduce quiescent hematopoietic stem cells. Similarly, AAV vectors have only been shown to transduce primate stem cells at a very low efficiency. 9 Consequently, as an alternative strategy, we and others have previously demonstrated that adenoviral vectors are an appropriate vehicle for transduction of hematopoietic cells. [10] [11] [12] Because adenoviruses do not normally integrate into the genome, they are only suited to studies where transient gene expression is sufficient. Our studies have shown that adenoviral vectors can infect a variety of hematopoietic cell types under the appropriate culture conditions. Importantly, adenoviral transduction is very inefficient when exogenous cytokines are withheld (CTJ, unpublished data). Therefore, a significant limitation to the use of adenoviruses is the requirement for cytokine stimulation. Similarly, the uptake kinetics of adenoviral vectors can also be limiting. Only a small percentage of primitive hematopoietic cells are known to express high levels of the adenovirus receptor, CAR-1 (V Rebel, personal communication). Therefore, it appears that adenoviral internalization into hematopoietic cells is mediated by secondary mechanisms that are much slower than generally observed for permissive cells. Typically, 24-48 h of continuous exposure is required to saturate adenoviral infection of primitive hematopoietic cells. 10 Given the limitations described above, we sought to further develop the use of adenoviruses to permit more efficient transduction of hematopoietic cells. Our primary objectives were to increase both the kinetics and efficiency of viral uptake, and to reduce or eliminate the need for exogenous cytokines. One strategy that has been widely employed is the use of polycations as an adjunct to the adenoviral vehicle. It has been shown that polycations such as poly-l-lysine, lipofectamine, and other cationic lipids can simply be mixed with viral stocks to generate a non-covalent virus-polycation complex (VPC). 13 Moreover, genetic modification of the terminus of the adenoviral fiber protein (to incorporate poly-lysine or other synthetic domains) 14, 15 results in more efficient transduction of a variety of cells that are not typically permissive to conventional adenoviral vectors. Furthermore, one recent report has shown that certain polycations are able to augment adenovirus infection of human CD34
+ cells derived from umbilical cord blood. 16 Consequently, we evaluated several cations with respect to gene transfer into primitive hematopoietic cells. One compound of particular interest, a fractured polyamidoamine dendrimer, 17 greatly enhanced the uptake of adenoviral vectors. Importantly, it was observed that not only was the efficiency of transduction increased when the dendrimer was used, but the kinetics of gene transfer were also markedly faster. The studies presented in this manuscript demonstrate that VPCs generated with this dendrimer can transduce both normal and leukemic cells, including those of a highly primitive phenotype, rapidly and more efficiently than conventional adenoviral vectors.
Successful gene transfer into primary tumor cells is of clinical relevance with respect to the generation of gene-modified tumor vaccines. Introduction of immunomodulatory genes into tumor cells to enhance immunogenicity and generate a tumor-specific immune response has been applied in the development of vaccines for solid tumors. 18, 19 In particular, the expression of genes such as B7.1 (CD80) has been identified as a powerful means to increase the immunogenicity of malignant cells. 20, 21 Rapid and efficient gene transfer into primary AML cells utilizing the VPC method thus becomes a potentially useful tool in the development of novel treatment strategies for AML.
Materials and methods

Cells
The KG-1 cell line was obtained from the American Type Culture Collection (ATCC) and maintained in Iscove's modified Dulbecco's medium (IMDM) with 10% fetal bovine serum (FBS). Normal human hematopoietic cells were obtained from surgical marrow harvest from allogeneic bone marrow donors. Leukemia cells were obtained from the peripheral blood and/or bone marrow of patients with a new diagnosis of acute myelogenous leukemia. Appropriate informed consent and Institutional Review Board approval was obtained for all sample collections. Mononuclear cells (MNCs) were isolated by standard ammonium chloride erythrocyte lysis or by density gradient centrifugation using Ficoll-Paque (Pharmacia, Uppsala, Sweden). MNCs were then washed twice with phosphate-buffered saline (PBS), and either placed in culture or in the case of normal marrow further processed to isolate CD34 + cells using the Miltenyi immunoaffinity device (varioMACS). In some cases, MNCs were cryopreserved in freezing medium (IMDM, 40% FBS, and 10% DMSO) at a concentration of 5 × 10 7 cells/ml.
Viruses
An adenoviral vector containing an E1/E3 deletion and using the cytomegalovirus (CMV) enhancer/promoter to drive expression of the EGFP (enhanced green fluorescent protein) gene was used for transduction of both normal and leukemic hematopoietic cells. The Ad-GFP virus was constructed using the CRE-Lox mediated recombination system, 22 and was kindly provided by Dr Stephen Hardy, Chiron Corp. An adenoviral vector carrying the E1/E3 deletion and using the CMV enhancer/promoter to drive expression of a human B7.1 (CD80) cDNA was used for Ad-B7 transductions (Ad-B7 virus generously provided by Dr Sophie Dessureault, Mt Sinai Hospital, Toronto). 23 Both viruses were propagated by infection of 293 cells. After 48 h, cells were collected, lysed by three freeze-thaw cycles, and subjected to two cycles of CsCI density gradient separation. 24 Purified virus was extracted from the gradient, aliquoted and stored in 30% glycerol at −80°C. The titer of infectious units (IU) was determined using Hela cells. The concentration of viral particles was determined by optical density assuming 1.0 OD 260 unit = 1 × 10 12 viral particles/ml.
Transductions
Cells were cultured in IMDM supplemented with 10% FBS and 10 units/ml penicillin and streptomycin at a concentration of 1-2 × 10 6 cells/ml. Infections were performed with or without 5 ng/ml interleukin-3 (IL-3) and 10 ng/ml stem cell factor (SCF, R&D Systems), 25 ng/ml granulocyte-colony stimulating factor (G-CSF) and 3 units/ml erythropoietin (Amgen), and 50 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF, Immunex). VPC were formed by mixing adenoviral particles with the polyamidoamine dendrimer (Superfect reagent, Qiagen) at a ratio of 5-10 × 10 9 particles per microgram and incubating at room temperature for 5 min (mixing performed in a 10-20 × volume of IMDM). The VPC was then added directly to the primary cell culture using a multiplicity of infection (MOI) of 250-500. In the interest of cell viability, a ratio of 3 g dendrimer to 1 × 10 6 cells was not exceeded. At indicated time points, cells were harvested, washed twice in PBS with 1% human serum albumin, and resuspended in culture medium as described above. Cells were incubated for a total of 48 h at 37°C prior to flow cytometric analyses.
Phenotypic analysis
All samples were analyzed using a Becton Dickinson FACScan or FACSvantage flow cytometer. Prior to infection, MNCs were phenotyped to determine the antigenic profile of the leukemic blast population. Phycoerythrin (PE) or fluorescein isothiocyanate (FITC) conjugated monoclonal antibodies specific to CD33, CD34, HLA-DR, CD13, CD7, CD15 (Becton Dickinson) and CD80 (Coulter) were used per standard procedures to identify the leukemic cells. Cells were also labeled with propidium iodide (PI) to assess cell viability. After infection, gene transfer efficiency was determined by assessing the percentage of normal or leukemic cells that were positive for GFP or CD80 in comparison to uninfected controls. For primary AML specimens, cell populations were gated on the appropriate antigenic markers (determined prior to infection) so that only leukemic cells were analyzed. Primitive normal cells and leukemic stem cells were identified by the antigenic criteria of CD34
A method for multiparameter flow cytometric analysis, Surface, Intracellular, and DNA (SID) analysis, was utilized to simultaneously assess surface phenotype and cell cycle status for primitive hematopoietic cells. The technique was used as previously described, 25 but was modified to permit the use of an additional fluorochrome. Specifically, cells were stained with CD34-biotin (Coulter) + Streptavidin-Red613 and CD38-APC (Becton Dickinson) to define the CD34
− phenotype. After surface antigen staining, cells were fixed in 0.5% ultrapure formaldehyde (Polysciences) and permeabilized with 0.1% Triton X-100. The nuclear antigen Ki-67 was then labeled with a PE-conjugated monoclonal antibody (Dako), and finally DAPI was added (2 m final concentration) to stain for DNA content. The resulting cell sample was then analyzed on a Becton Dickinson FACSVantage flow cytometer modified to emit laser lines of 350 nm, 488 nm, and 633 nm. DNA level was detected by excitation of DAPI from the 350 nm line, PE and Red613 were excited by the 488 nm line, and APC was excited by the 633 nm line. The transgene marker, GFP was excited by the primary laser (488 nm). The instrument was equipped with crossbeam compensation to control emission bleedover problems; however, at the fluorescence levels used this phenomenon was generally not encountered. The configuration of the 350 nm and 633 nm lasers was co-linear, but with electronic compensation between the respective detectors (FL4 vs FL5), UV and APC signals were easily resolved (the emission spectra of DAPI is so broad that it is sometimes seen in the APC channel).
Statistics
Statistical validity of data shown in Tables 1 and 2 was determined by calculating P values using a two-tailed Student's t-test.
Lymphocyte cultures
To establish functionality of the CD80 molecule introduced by VPC gene transfer, HLA-A2
+ peripheral blood mononuclear cells (PBMC) from three normal donors were co-cultured with HLA-A2
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Results
Formation and use of VPCs for gene transfer
To form the virus-polycation complex (VPC), the dendrimer was combined in varying ratios with the Ad-GFP virus.
Initially we tested for efficiency and kinetics of gene transfer into the leukemic cell line KG-1. As the concentration of polycation was increased, the infection efficiency also increased. However, at higher levels of dendrimer we began to observe toxicity to the target cells. The optimal concentration was 5-10 × 10 9 viral particles/g dendrimer. VPCs were then tested on primary cells using normal human CD34 + cells derived from bone marrow specimens. A VPC formed using the Ad-GFP virus was directly compared to the virus alone. Figure 1 shows the results in terms of infection efficiency vs time of infection. At the indicated time points, the samples were washed to remove excess virus or VPC. As can be seen from the Figure, the VPC mediated a rapid transduction event that was largely complete (approximately 75% of maximal) within 15 min. In contrast, the adenovirus alone had only achieved approximately 10% of maximal infection at the same time point. As seen previously, the adenovirus alone was only capable of approximately 30% transduction overall, whereas the VPC permitted a significantly higher level of gene transfer. Therefore, the VPC gene transfer vehicle appeared to overcome limitations of both low gene transfer efficiency and slow kinetics of viral uptake in normal human CD34 + cells.
Transduction of primitive hematopoietic cells
Primitive hematopoietic cells are characteristically almost entirely quiescent and have a cell surface phenotype of CD34
− . Thus, to further establish that VPCs were capable of transducing primitive cells, we examined gene transfer efficiency using a method of multiparameter flow cytometry that permits analysis of hematopoietic cells in G0. The technique, referred to as SID (surface, intracellular, and DNA) analysis was utilized to simultaneously assess surface phenotype and cell cycle status for primitive hematopoietic cells. Using a five-color flow cytometric strategy, we analyzed the efficiency of VPC gene transfer into quiescent CD34 Figure 2a shows the overall CD34 vs CD38 profile, while Figure 2b shows the DNA (DAPI) vs Ki-67 profile of CD34
− cells in the R2 gate. As noted in Figure 2b , cells that are negative for nuclear antigen Ki-67 and have a diploid DNA content (lower left quadrant) are defined as being in G0. Thus, the cells that fall in the box designated R3 are CD34
− and in the G0 stage of cell cycle. For the same sample, the lower panels (Figures 2c and d) 
Transduction of primary AML cells
As opposed to observations in normal hematopoietic cells, adenoviruses have been reported to infect malignant hematopoietic cells with varying efficiency. 26, 27 Given the enhanced transduction efficiency observed in normal CD34
+ hematopoietic cells, we next evaluated the ability of VPCs to transduce malignant hematopoietic cells. Figure 3a shows a typical AML sample with a high blast cell count. Figures 3b and c show the uninfected control vs VPC infected cells from the same sample after a 24-h transduction. Clearly, the VPC was capable of highly efficient transduction of AML cells. To further examine this finding, primary AML tumor cells were evaluated from 15 previously untreated AML patients. Samples were analyzed with respect to efficiency of gene transfer and growth factor dependence for a standard adenoviral vector (Ad-GFP) vs the same vector utilized as a VPC (data summarized in Table 1 ). VPC infections were consistently more efficient than infections with standard adenoviral vectors. In the presence of cytokines, the average infection efficiency for VPC infections was 68% vs 45% for standard adenovirus infections (P = 0.006); without cytokines, average infection efficiency was 58% using a VPC and 42% using standard adenovirus (while not statistically significant in the absence of cytokines (P = 0.17), when kinetics of infection are considered we still believe that the VPC is advantageous, see Table 2 ). Interestingly, AML cells appeared to be much less dependent on the presence of cytokines for adenoviral gene transfer than previously observed for normal (nonmalignant) primary cells. Although the absolute efficiency of infection was not dramatically reduced when cytokines were withheld, it should be noted that the mean fluorescent intensity of the GFP reporter was always markedly lower in the absence of cytokines. This suggests that among cells in the population permissive to adenovirus infection, either the infection event or the subsequent expression of the viral transgene was enhanced by the presence of exogenous cytokines.
As shown previously in normal CD34 + cells, a striking increase in uptake kinetics was observed in AML cells with the VPC vs standard adenoviral vectors. Table 2 shows the kinetics of VPC vs conventional adenovirus infections for six experiments using AML cells that were infected for 2 or 48 h. Gene transfer efficiency for each infection was evaluated at 48 h post-infection. Two-hour infections with VPCs were substantially more efficient than 2-h infections with standard adenoviral vectors (P = 0.0014). Cells infected with VPCs for only 2 h achieved 71% (51/71) of the infection efficiency achieved with 48-h VPC infections. By comparison, cells infected for 2 h with standard adenovirus vectors achieved only 23% (10/43) of the gene transfer efficiency observed in 48-h infections. Overall, the average efficiency of 2-h infections using VPC was 51% vs 10% for standard adenovirus infections.
To demonstrate that VPC transduction was also effective for 28, 29 Using multiparameter flow cytometry as described above, AML samples were examined to characterize such cells. Figure 4 shows one example of gene transfer into phenotypically primitive leukemic cells, utilizing the VPC method of transduction. Clearly, the CD34
− sub-population can be readily transduced by the VPC. Cell cycle studies indicate that like normal stem cells, the primitive leukemic cells are also highly quiescent (data not shown).
Ad-B7 transduced primary AML cells
Given the ability to mediate rapid and efficient gene transfer into primitive leukemia cells, one application of such technology is to generate gene-modified tumor vaccines. With recent advances in identifying factors regulating immune responses, we turned our focus to investigating the transduction of primary AML cells with immunomodulatory genes. First, we examined AML cells for the expression of molecules relevant to immune stimulation. One critical molecule for the stimulation of antigen-specific lymphocytes is the B7.1 protein (CD80). The same samples used in Table 1 for analysis of VPC transduction were also analyzed for the expression of endogenous CD80 both before and after culture with the gene transfer vehicle. In no case did we observe more than 5% weakly positive leukemia cells, and in many cases expression was undetectable (data not shown). Furthermore, we also tested culture in interferon-␥ as a means to up-regulate CD80 but again did not see more than 5% CD80 + cells. Thus,given the negligible levels of endogenous CD80, we reasoned that this molecule was a good candidate for use in the generation of an AML gene-modified tumor vaccine.
Using an adenovirus vector encoding the human CD80 gene, 23 we tested gene transfer into primary AML cells in the context of VPC-mediated gene transfer. The results indicated that the efficiency of the Ad-B7 virus was comparable to the Ad-GFP virus. Figure 5 shows one example of primary AML cells infected with the Ad-B7 virus. As seen for the Ad-GFP virus, gene transfer is readily apparent and significantly better using the VPC conditions (38% adenovirus only vs 64% VPC). Thus, adenovirus-mediated gene transfer appears to be an effective means of achieving efficient expression of an exogenous CD80 molecule in primary AML cells.
Lymphocyte stimulation by Ad-B7 transduced AML cells
+ peripheral blood mononuclear cells (PBMC) from three normal donors were co-cultured for 5 days with HLA-A2
+ AML tumor cells that were either nontransduced or transduced with Ad-B7 or Ad-GFP. The results ( Figure 6 ) show that none of the samples responded to nontransduced or Ad-GFP transduced tumor, but that significant incorporation of 3 H-thymidine occurred in response to Ad-B7-transduced cells. These data suggest that the CD80 expressed on AML cells by gene transfer enhances the allogeneic proliferative response of lymphocytes challenged by tumor cells and is not the result of non-specific stimulation by basal level adenoviral proteins.
Figure 5
Ad-B7 transduction of AML cells. Freshly isolated primary AML cells were transduced with either the Ad-B7 virus alone (upper panel) or the Ad-B7 virus complexed as a VPC (lower panel) at an MOI = 250. At 48 h post-infection, the blast population was analyzed with respect to expression of B7 (CD80). For each panel the uninfected control is shown as a dashed line and the infected sample with a bold line. Background from the uninfected control was 3%. Gene transfer efficiency for the virus alone was 38% and the VPC was 64%.
Discussion
Numerous studies have investigated gene transfer technologies for hematopoietic cells. Such approaches have utilized predominantly either viral or non-viral vehicles for gene transfer. [30] [31] [32] In the present study, we utilized components of both viral and non-viral systems to create a hybrid vehicle. By combining an adenoviral vector with a synthetic polyamidoamine dendrimer to create a VPC, we have shown that such a vehicle can reproducibly infect both normal and leukemic human hematopoietic cells of very primitive phenotype. Moreover, the use of this type of VPC appears to enhance the host range of the adenoviral vehicle and accelerate the kinetics of uptake.
Previously, many investigators have successfully employed retroviral vectors to infect hematopoietic cells, however, transduction of the most primitive cells (quiescent CD34 can be easily generated in high concentrations (10 12 viral particles/ml), and typically express their transgenes very effectively. In non-hematopoietic cells, permissivity to adenovirus infection is associated with integrins ␣v␤3 or ␣v␤5 33 and the recently described receptor CAR-1. 34 Our analyses of CD34 + hematopoietic cells did not reveal the presence or induction of such integrins, even in the presence of cytokines (data not shown). Moreover, the expression of CAR-1 appears to be limited to a small subset of CD34 + cells (V Rebel, personal communication). Thus, the mechanism of adenoviral infection for hematopoietic cells is as yet largely uncharacterized. Given the inefficient kinetics of uptake for adenovirus alone (24-48 h), it seems likely that the process is not highly evolved and indeed may involve a relatively non-specific secondary pathway.
Due to the extensive interest in adenoviral vectors for transduction of non-hematopoietic tissues, a variety of methods have been explored to improve adenoviral gene transfer. Some investigators have attempted to enhance infection efficiencies by using molecular techniques to re-engineer the adenoviral surface structure. 14, 35 Other investigators have modified the behavior of adenoviruses by simply mixing the virus with various cationic compounds. 13 Both of these approaches have clearly indicated that modification of the adenoviral surface can mediate more efficient infection of cells that are typically non-permissive. As a consequence of these studies, we attempted to develop similar strategies that would enable better transduction of primitive hematopoietic cells. In so doing, we have found that a fractured polyamidoamine dendrimer 17 (also known as a transfection reagent called 'Superfect') can be complexed with an adenovirus vector to yield superior transduction of both normal and leukemic hematopoietic cells.
The use of adenoviral vectors to infect hematopoietic cells has several potential applications. For example, with the rapid progress in identifying stem cell genes, 36 it will clearly be important to analyze such molecules in the context of primary tissue. Thus, the ability to readily transduce primitive tissue should provide a useful means of genetic and functional analysis. Furthermore, several investigators have shown that bicistronic vectors can be easily generated for adenoviral as well as other types of vectors. [37] [38] [39] Consequently, one can envision the use of a cell autonomous marker such as GFP in conjunction with a stem cell gene (eg SCL, Gata-1, PU.1, etc) so that biological changes can be monitored and characterized for specific cells. In addition, the capacity of adenoviral vectors to transduce non-dividing cells is of critical importance for the analysis of hematopoietic stem cells. While recent developments in the lentivirus vector field suggest that other vectors may be useful for quiescent cell types, as yet, none are as readily generated as the conventional adenovirus vectors and VPCs described in this study.
Transduction of primitive leukemia cells also has clear potential for clinical gene therapy studies. Ongoing efforts to treat multiple types of cancer are using gene-modified tumor vaccines as a strategy to enhance the anti-tumor immune response. 40 Currently among the most commonly used genes are cytokines or costimulatory molecules such as B7.1 (CD80). CD80 acts through binding the CD28 ligand present on T-lymphocytes and provides a signal critical for their proliferation, differentiation, and clonal expansion. Hematopoietic tumors are particularly good targets for costimulatory molecule transduction because they generally lack expression of CD80 (confirmed by our observations), but express MHC class I and class II molecules on the cells' surface, and possess the potential to act as antigen presenting cells in certain situations. Several studies in murine model systems have indicated that expression of CD80 results in a potent anti-leukemia response. 41, 42 In addition, other studies using very inefficient gene transfer techniques have suggested that expression of CD80 in human AML cells can also evoke a stronger lymphocyte response. 43 The studies described in this report demonstrate that CD80 can be readily expressed at high levels in primary AML tumor cells, and that the expression of this gene appears to increase growth of allogeneic T-lymphocytes.
The donor lymphocytes used for these studies were matched to the AML cells at the HLA-A2 locus, but were disparate at other loci. Thus, we cannot say whether the expression of CD80 directly causes the proliferative response or simply augments a low-level allogeneic response. Nonetheless, given the results from previous studies using gene-modified tumor cells, the data suggest that generation of CD80-expressing AML tumor vaccines may be a viable approach to the treatment of leukemia. Furthermore, because our method is also effective for the transduction of CD34
− leukemic cells, it is more likely that an anti-tumor response will be generated that results in immune recognition of the most primitive leukemic cell types. Given recent studies that have identified a type of 'leukemic stem cell' within bulk AML clones, 28, 29 the ability to specifically target this primitive subset may be critical to the ultimate success of immunotherapy strategies. In the future we will continue to evaluate the use of VPCs for generation of gene-modified tumor cell vaccines with particular focus on inducing an immune response to leukemic stem cells. While there is currently no precedent for use of the fractured polyamidoamine dendrimer in clinical studies, we are aware of no reason why it could not be certified for at least ex vivo gene transfer studies.
In summary, we have developed a novel method for the rapid and efficient transduction of primitive, non-cycling human hematopoietic progenitors and primary leukemia (AML) cells. These results have been obtained using both a reporter gene and a gene with clear immune regulatory potential. The transduction of primary human hematopoietic cells will permit future investigation of the characteristics and behavior of hematopoietic stem cells. Furthermore, the transduction of primary human AML cells is an initial step toward the use of gene therapy in the treatment of human leukemias. We have postulated one potential clinical application for gene transduction of AML cells. These data support the development of other clinical and basic science applications.
